Back to Search
Start Over
Pilot trial of high-dose vitamin C in critically ill COVID-19 patients.
- Source :
- Annals of Intensive Care; 1/9/2021, Vol. 11 Issue 1, p1-12, 12p
- Publication Year :
- 2021
-
Abstract
- Background: Few specific medications have been proven effective for the treatment of patients with severe coronavirus disease 2019 (COVID-19). Here, we tested whether high-dose vitamin C infusion was effective for severe COVID-19. Methods: This randomized, controlled, clinical trial was performed at 3 hospitals in Hubei, China. Patients with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the ICU were randomly assigned in as 1:1 ratio to either the high-dose intravenous vitamin C (HDIVC) or the placebo. HDIVC group received 12 g of vitamin C/50 ml every 12 h for 7 days at a rate of 12 ml/hour, and the placebo group received bacteriostatic water for injection in the same way within 48 h of arrival to ICU. The primary outcome was invasive mechanical ventilation-free days in 28 days (IMVFD28). Secondary outcomes were 28-day mortality, organ failure (Sequential Organ Failure Assessment (SOFA) score), and inflammation progression (interleukin-6). Results: Only 56 critical COVID-19 patients were ultimately recruited due to the early control of the outbreak. There was no difference in IMVFD28 between two groups (26.0 [9.0–28.0] in HDIVC vs 22.0 [8.50–28.0] in control, p = 0.57). HDIVC failed to reduce 28-day mortality (P = 0.27). During the 7-day treatment period, patients in the HDIVC group had a steady rise in the PaO<subscript>2</subscript>/FiO<subscript>2</subscript> (day 7: 229 vs. 151 mmHg, 95% CI 33 to 122, P = 0.01), which was not observed in the control group. IL-6 in the HDIVC group was lower than that in the control group (19.42 vs. 158.00; 95% CI -301.72 to -29.79; P = 0.04) on day 7. Conclusion: This pilot trial showed that HDIVC failed to improve IMVFD28, but might show a potential signal of benefit in oxygenation for critically ill patients with COVID-19 improving PaO2/FiO2 even though. [ABSTRACT FROM AUTHOR]
- Subjects :
- COVID-19
VITAMIN C
CRITICALLY ill
VITAMIN B2
SARS-CoV-2
Subjects
Details
- Language :
- English
- ISSN :
- 21105820
- Volume :
- 11
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Annals of Intensive Care
- Publication Type :
- Academic Journal
- Accession number :
- 148024740
- Full Text :
- https://doi.org/10.1186/s13613-020-00792-3